Visão geral da empresa
A clinical-stage biopharmaceutical company, Roivant Sciences Ltd. focuses on the end-to-end lifecycle of medicines and technologies, encompassing discovery, development, and commercialization efforts. The enterprise operates within the healthcare sector, specifically targeting the biotechnology industry, a domain characterized by high research and development intensity and significant regulatory hurdles. As of the latest reporting period, the company's total market capitalization stands at $20.28B, while its trailing twelve-month revenue amounts to $13.31M, and it employs approximately 750 individuals. The disparity between the substantial market capitalization of $20.28B and the minimal annual revenue of $13.31M indicates that the company's valuation is driven primarily by the potential value of its clinical product candidates, such as IMVT-1402, rather than current commercial earnings. This structural dynamic is typical for clinical-stage entities where investor expectations are anchored in future pipeline milestones rather than immediate financial performance, placing the company in a position where its stock price reflects anticipated long-term development success rather than current operational profitability.
Saúde financeira
The company reported a revenue of $13.31M for the trailing twelve months, yet it recorded a net income of $-809,240,000 and an EBITDA of $-1,264,381,952, revealing a cost structure where operating expenses vastly outweigh current revenue generation. The free cash flow stands at $-334,342,944, indicating that the company is consuming cash reserves to fund its operations and development activities rather than generating surplus liquidity. Analysis of the margin profile shows a gross margin of 0.0%, an operating margin of -16965.3%, and a profit margin of 0.0%, figures that collectively signal a business model currently devoid of profitability at the gross level and facing extreme operating inefficiencies relative to its current sales base. On the balance sheet, the company holds $4.53B in cash against $108.94M in debt, resulting in a debt-to-equity ratio of 2.19, which suggests a highly leveraged capital structure despite the absolute volume of cash on hand. The current ratio is reported at 30.66, a metric that implies an exceptionally strong short-term liquidity position capable of meeting obligations many times over. Finally, the return on equity is -19.1% and the return on assets is -14.5%, metrics that reveal that management's current allocation of capital is resulting in value destruction rather than value creation for shareholders.
Avaliação de valorização
The trailing P/E ratio is listed as N/A due to the lack of net income, while the forward P/E stands at -27.46, a negative figure that implies the market is pricing in future losses rather than anticipating near-term earnings recovery. The price-to-book ratio is 4.71, indicating that the market values the company at a significant premium over its net asset book value, a common characteristic for biotechnology firms with valuable intellectual property portfolios. Alternative valuation metrics such as the price-to-sales ratio of 1523.35 and an EV/EBITDA of -13.10 further illustrate that standard profitability-based valuation models are inapplicable, necessitating reliance on pipeline-driven metrics for assessment. The stock's trading range over the past year has fluctuated between a 52-week low of $8.73 and a high of $30.33. Without a specific current share price provided in the source data to calculate the exact percentage deviation, the valuation is inherently tied to the extreme volatility suggested by the beta coefficient. The beta value is 1.21, which signifies that the stock's price volatility is expected to be 21% higher than the broader market movements, reflecting the heightened risk profile associated with clinical-stage biotechnology assets.
Growth & Income
Revenue growth year-over-year is -77.8%, while earnings growth is N/A due to the absence of prior period earnings, a situation where the decline in revenue suggests a contraction in current commercial sales or licensing activities. Since earnings are negative, the comparison of earnings growth to revenue growth is not mathematically possible, but the negative revenue trend implies that the company is currently shrinking in terms of top-line performance. The company does not pay a dividend, as evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all available cash is retained for reinvestment into research, development, and operational continuity rather than distribution to shareholders. Consequently, the overall growth and income profile is defined by significant revenue contraction and a complete absence of cash returns to investors, relying entirely on the conversion of its substantial cash hoard into future commercial success.